First Real-World Data Study Reaches Enrollment Goal

PrECOG, LLC’s PrE1702 study has successfully reached its target patient accrual goal, thanks to the outstanding efforts of participating sites, investigators, research staff, and patient volunteers. Special commendations go to study chair Suzanne Cole, MD (UT Southwestern/Simmons Comprehensive Cancer Center) and co-chair Maya Khalil, MD (University of Alabama/UAB Comprehensive Cancer Center), for their dedication and expertise in guiding this groundbreaking real-world data (RWD) study.

RWD is becoming increasingly important in today’s healthcare decision-making. PrE1702 is the first study of its kind from PrECOG and ECOG-ACRIN, and the first study by these groups to receive funding from the US Food and Drug Administration. It is evaluating the feasibility of using RWD, collected through a registry of well-characterized patients, to compare outcomes among individuals with EGFR-mutated non-small cell lung cancer receiving osimertinib-based treatment outside of a clinical trial setting, including osimertinib alone or in combination with chemotherapy or immunotherapy. Researchers will compare these outcomes with those from EA5182.

Through this study, investigators expect to gain a better understanding of the impact of these commonly prescribed treatments. Results will also aid in creating a roadmap to guide future RWD collection strategies. Read the Trial Spotlight on PrE1702.

ECOG-ACRIN Welcomes New Advocates

Please join us in welcoming five new members of the Cancer Research Advocates Committee (CRAC), who bring the patient perspective to ECOG-ACRIN scientific committees. CRAC members, who are cancer survivors and caregivers, advise research teams at key points during clinical trials. From design and informed consent review through activation and results reporting, they represent patient needs and concerns while offering unique experiences and connections to their networks of cancer support organizations, patients, and other advocates for bi-directional communication.

We are pleased to welcome Laurie Adami (Lymphoma Committee), Jud Kimmel (Gastrointestinal Cancer Committee), Greg Lund (Genitourinary Cancer Committee), Stefenie Perry (Lymphoma Committee), and Dr. Jeff Rubin (Myeloma Committee). Learn more and view the full CRAC roster.

ASTRO Session Features DECREASE Study and Its Leaders

The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting features the education session Radiotherapy Treatment Planning for Anal Cancer: Personalized Radiation and Modern Techniques, on Sunday, September 27, from 5:00-6:00 PM (Eastern Time). Joshua E. Meyer, MD (Fox Chase Cancer Center), will moderate the session and present DECREASE-EA2182: A Model for Precise Contouring of Early-Stage Anal Cancer. Jennifer A. Dorth, MD (University Hospitals – Seidman Cancer Center, Cleveland), study chair for the DECREASE trial , will discuss evidence-based approaches to radiation planning and treatment for early-stage anal cancer. The ASTRO meeting takes place in Boston from September 26-30, and this session will be available via livestream. View the session details.

Reminder: Register for the Fall 2025 Group Meeting

There is still time to register for the ECOG-ACRIN Fall 2026 Group Meeting, taking place Tuesday, October 20–Thursday, October 22, in Philadelphia. View the schedule on the Group Meeting website and register for three days of engaging sessions highlighting the latest in basic, clinical, and translational research.

Featured Sessions 

Group leaders encourage attendees to take part in the following sessions (all times below are Eastern Time):

Tuesday, October 20

• Young Investigators Symposium | 9:00-11:00 AM
• Robert L. Comis, MD Translational Science Symposium | 12:00-2:00 PM
• Task Force on Career Advancement | 6:00-7:00 PM
• Task Force on Career Advancement Networking Hour- All Welcome | 7:00-8:00 PM

Wednesday, October 21

• General Session | 9:00-11:00 AM
• Social Determinants of Health Working Group | 3:30-4:30 PM
• TMIST Update and Education Session | 5:00-6:00 PM
• Reception | 7:30-9:30 PM

Thursday, October 22

• Pharmacist, Oncology Nurse, CRA/Data Manager Education Symposium | 8:00-10:00 AM